OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of “Reduce” by Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPK) have received an average rating of “Reduce” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $1.55.

A number of research analysts have recently commented on the company. Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.19 on Monday. The company has a market cap of $898.56 million, a P/E ratio of -4.41 and a beta of 1.48. The firm has a fifty day moving average price of $1.36 and a 200 day moving average price of $1.27. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.61.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $124.20 million for the quarter, compared to analysts’ expectations of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.OPKO Health’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period last year, the firm earned ($0.10) earnings per share. Sell-side analysts predict that OPKO Health will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its position in OPKO Health by 150.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after acquiring an additional 3,600,378 shares during the period. Millennium Management LLC lifted its position in OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares during the period. AQR Capital Management LLC lifted its position in OPKO Health by 466.7% during the 1st quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after acquiring an additional 1,324,988 shares during the period. OP Asset Management Ltd acquired a new stake in OPKO Health during the 1st quarter worth approximately $1,257,000. Finally, HRT Financial LP purchased a new position in shares of OPKO Health in the 4th quarter valued at approximately $851,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.